Saudi Arabia-based Tabuk Pharmaceutical Manufacturing Company, a leading pharmaceutical company in the Middle East and North Africa (Mena) region, has entered into an in-licensing agreement with Dong A, a leading Korean company, to in-license Zydena Udenafil tablets.

Under this agreement, Dong A will grant Tabuk exclusive rights to carry out the manufacturing processes under license, commercialise and distribute Zydena in the kingdom and the Gulf area, said a statement from the company.

This project demonstrates Tabuk's continued commitment to patients and to offering new medicines within an ongoing collaboration with global partners to deliver on its mission to help improve the lives of patients, it said.

Dr Rana Azzam, senior vice president of business development, Tabuk, said: “I am very pleased by this partnership and the future business we will build together, we look forward to continuing to expand our portfolio and better serving patients' needs.”

Chae J Lee, senior vice president of global business, Dong-A, said: “We are very excited to establish this collaboration with Tabuk, a highly respected pharmaceutical company in the region, for Zydena, Dong-A's innovative PDE-5 inhibitor for patients suffering from erectile dysfunction(ED).”

“Through our close collaboration, we look forward to making a positive impact on ED patients' quality of life in the region,” he added. – TradeArabia News Service